About Battelle Ventures
Battelle Ventures is a venture capital firm founded in 2003. It is primarily based out of Trenton, United States. As of Mar 2015, Battelle Ventures has invested in 20 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Post IPO round of Champion Oncology Overall, Battelle Ventures portfolio has seen 2 IPOs and 7 acquisitions including key companies like Champion Oncology, Bionano and NuPathe. A lot of funds co-invest with Battelle Ventures, with names like Iternal sharing a substantial percentage of its portfolio. Battelle Ventures has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Battelle Ventures' List of Top Investments
Battelle Ventures has a portfolio of 20 companies. Their most notable investments are in BioVigilant and RemoteReality.Their portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 9 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by Battelle Ventures:1. Rajant
Provider of industrial wireless mesh network solutions for various industries. The company offers adaptable, flexible, and mobile networking for connecting and controlling assets and personnel. Products include wireless nodes, network management tools, and accessories. The company serves markets including defense, mining, oil and gas, utilities, and transportation. The company's technology supports data, voice, and video communications.
Key facts about Rajant
- Founded Year: 2001
- Location: Malvern (United States)
- Stage: Series B
- Total Funding till date: $8.05M
- Employee Count: 257 as on May 31, 2026
- Investors: Ben Franklin Technology Partners, Ben Franklin Technology Partners and 2 Others
- Latest Funding Round: Series B, Apr 13, 2017, $*****
- Highlight: Editors' Pick
Oncology CRO providing preclinical and clinical research services globally. The company accelerates oncology research by offering end-to-end research and development solutions. Specializing in preclinical and clinical specialty testing, the company drives excellence in drug development programs. Services include in vivo models, radiopharmaceutical testing, ex vivo platforms, and early drug discovery solutions. Advanced analytical solutions such as flow cytometry, next-generation sequencing, and histology are offered. The company provides a comprehensive multi-omics molecular data center, supporting programs from target to biomarker discovery. The mission is to improve patients’ lives through innovative solutions in cancer drug development. The company partners with pharmaceutical and biotech companies, providing clinically relevant preclinical models and advanced clinical specialty testing solutions. The Lumin platform offers real-time insights into tumor genetics and therapeutic responses, enhancing precision in oncology research.
Key facts about Champion Oncology
- Founded Year: 1985
- Location: Hackensack (United States)
- Annual Revenue: $50M - $100M as on Apr 30, 2025
- Stage: Public
- Employee Count: 185 as on May 31, 2026
- Investors: Perceptive Advisors, PAR Capital Management and 5 Others
- Latest Funding Round: Post IPO, Mar 12, 2015, $*****
- Highlight: Public
3. Bionano
Provider of genome analysis solutions to researchers and clinicians. It offers Saphyr system that uses a non-sequencing based optical mapping technology to analyse extremely long strands of genomic DNA. It is used for detecting genomic variants missed by next-generation sequencing (NGS) technologies and conventional cytogenetic techniques.
Key facts about Bionano
- Founded Year: 2002
- Location: San Diego (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $124M
- Employee Count: 171 as on May 31, 2026
- Investors: Domain Associates, Monashee Investment Management and 17 Others
- Latest Funding Round: Post IPO, May 24, 2024, $*****
- Highlight: Public
Transcatheter cardiac repair devices improving structural heart disease treatment. The company designs, manufactures, and commercializes disruptive catheter-based technologies for transcatheter cardiac repair (TCR) procedures. Their focus is on replicating established surgical structural heart repair procedures percutaneously, aiming to eliminate the need for open-heart surgery and cardiopulmonary bypass. The company strives to improve patient outcomes, reduce procedure time, and shorten hospital stays. Their initial focus is on addressing unmet needs in transcatheter mitral and tricuspid valve repair. They are ISO certified and have a manufacturing area. Their technology transforms open surgical procedures to transcatheter cardiac repair procedures.
Key facts about Micro Interventional
- Founded Year: 2010
- Location: Newtown Square (United States)
- Stage: Series D
- Total Funding till date: $37.8M
- Employee Count: 17 as on Jun 26, 2025
- Investors: Activate Venture Partners, Originate Ventures and 5 Others
- Latest Funding Round: Series D, Dec 02, 2022, $*****
- Highlight: Editors' Pick
5. NuPathe
NuPathe developed therapeutics for neurological and psychiatric disorders. Its platform technology LAD™, or Long-Acting Delivery, is a biodegradable implant technology that allows delayed release of medication, even upto a few months. NuPathe’s lead product candidate, NP101, was an active, single-use, transdermal sumatriptan patch for treating migraines. In addition, the company had products for schizophrenia and bipolar disorder, attempting to address the problem of patient non-compliance with neuropsychiatric diseases. In Jan 2014, Teva acquired NuPathe for $114 million upfront.
Key facts about NuPathe
- Founded Year: 2005
- Location: Conshohocken (United States)
- Stage: Acquired
- Total Funding till date: $45.5M
- Employee Count: 18 as on Dec 31, 2022
- Investors: Quaker Partners Management, Hercules Capital and 7 Others
- Latest Funding Round: Post IPO, Nov 06, 2012, $*****
- Highlight: Acquired
Battelle Ventures' Investments by Stage
Battelle Ventures has made 9 investments in Series A stage with an average round size of $4.99M, 5 investments in Series B stage with an average round size of $12.6M and 2 investments in Seed stage with an average round size of $1.25M.Stage of entry | No. of Investments |
|---|---|
Series A | 9 |
Series B | 5 |
Seed | 2 |
Series C | 2 |
Post IPO | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Battelle Ventures' Investments by Sector
Battelle Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Energy Tech, Sustainability Tech and Enterprise Applications. Notably, it has invested in 16 Enterprise (B2B) companies, 16 Tech companies, 7 Software companies and at least 4 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
High Tech | 6 |
Energy Tech | 4 |
Sustainability Tech | 4 |
Enterprise Applications | 3 |
Others | 11 |
Note: We have considered here, only first round of investments
Battelle Ventures' Investments by Geography
Battelle Ventures has made most investments in United States (20).Battelle Ventures' recent investments
Battelle Ventures has not made any investment in 2026 so far.Here are the most recent investments by Battelle Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 12, 2015 | United States | Post IPO | 8966 | ||
Dec 31, 2014 | United States | Series C | 7833 | [+3] | |
Sep 26, 2013 | United States | Series B | 7370 | [+1] | |
Jan 14, 2013 | United States | Series B | 7381 | ||
Dec 17, 2012 | United States | Series A | 8116 |
IPOs and Publicly Listed companies in Battelle Ventures' Portfolio
2 of Battelle Ventures' portfolio companies have become public. Bionano got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2018 at marketcap of $69.9M and Champion Oncology got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Battelle Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 21, 2018 | Mar 26, 2008 | Series A | 6889 | |
Mar 25, 1986 | Mar 12, 2015 | Post IPO | 5486 |
Acquired companies in Battelle Ventures' Portfolio
7 companies from Battelle Ventures' portfolio have been acquired. The most recent acquisition was Nistica in Sep 2018 by Molex for $*****.Here are Battelle Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 21, 2018 | Feb 25, 2008 | Series B | 1426 | |
Jan 21, 2014 | Jul 24, 2008 | Series B | 2609 | |
Feb 15, 2012 | Oct 17, 2005 | Series C | 3458 | |
Sep 07, 2010 | May 18, 2006 | Unattributed | 7549 | |
Jun 01, 2009 | Jun 22, 2005 | Series A | 1722 |
Team profile of Battelle Ventures
Battelle Ventures has a team of 2 members including 2 Partners located in Ireland. Battelle Ventures' team does not sit on the board of any company as of now.Co-investors of Battelle Ventures
Over the past 21 years, 90 investors have co-invested in Battelle Ventures's portfolio companies. This includes only funds.
- Invested before Battelle Ventures: Ben Franklin Technology Partners, HHS and 26 others have invested in rounds before Battelle Ventures. There are 2 companies where Ben Franklin Technology Partners has invested before Battelle Ventures and 2 companies where HHS has invested before Battelle Ventures.
- Top Co-investors of Battelle Ventures: 32 investors entered a company along with Battelle Ventures. These include investors like Iternal (7 companies).
- Invested after Battelle Ventures: A total of 30 investors have invested in Battelle Ventures's portfolio after their investments. Top Investors include Iternal (3 companies), National Science Foundation (3 companies) and OSTI (2 companies).
Recent News related to Battelle Ventures
•
•
Microsoft Word - BioNanomatrix_Secures 23 3M_ Series B _2_.docBionano Genomics•Mar 17, 2011•Bionano Genomics, Domain Associates, Battelle Ventures, KT Venture Group
•
Nistica Closes $8.5M Equity and Debt Financing Round |FinSMEsFinSMEs•Feb 01, 2011•Nistica, Battelle Ventures, Novitas Capital, Fujikura and 2 others
•
Nistica Closes on $8.5M in Equity, Debt – Financeseriouslyfinance.com•Feb 01, 2011•Nistica, Battelle Ventures, Novitas Capital, Fujikura and 2 others
•
Nistica Closes $6.5M Series C Financing |FinSMEsFinSMEs•Mar 22, 2010•Nistica, Battelle Ventures, Novitas Capital, Fujikura and 2 others
•
UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics - Tech Transfer e-News - Tech Transfer CentralTech Transfer Central•Feb 03, 2010•NellOne, Battelle Ventures
•
•
SmartSynch Raises $20 Million - PE HubPE Hub•May 22, 2008•SmartSynch, Battelle Ventures, Kinetic Ventures, UBS and 3 others
•
•
